  In carbon-ion radiotherapy, single-beam delivery each day in alternate
directions has been commonly practiced for operational efficiency, taking
advantage of the Bragg peak and the relative biological effectiveness (RBE) for
uniform dose conformation to a tumor. The treatment plans are usually evaluated
with total RBE-weighted dose, which is however deficient in relevance to the
biological effect in the linear-quadratic model due to its quadratic-dose term,
or the dose-fractionation effect. In this study, we reformulate the
extrapolated response dose (ERD), or synonymously BED, which normalizes the
dose-fractionation and cell-repopulation effects as well as the RBE of treating
radiation, based on inactivation of a single model cell system and a typical
treating radiation in carbon-ion RT. The ERD distribution virtually represents
the biological effect of the treatment regardless of radiation modality or
fractionation scheme. We applied the ERD formulation to simplistic model
treatments and to a preclinical survey for hypofractionation based on an actual
prostate-cancer treatment of carbon-ion radiotherapy. The proposed formulation
was demonstrated to be practical and to offer theoretical implications. In the
prostate-cancer case, the ERD distribution was very similar to the
RBE-weighted-dose distribution of the actual treatment in 12 fractions. With
hypofractionation, while the RBE-weighted-dose distribution varied
significantly, the ERD distribution was nearly invariant, implying that the
carbon-ion radiotherapy would be insensitive to fractionation. However,
treatment evaluation with simplistic biological dose is intrinsically limited
and must be complemented in practice somehow by clinical experiences and
biology experiments.
